Victor Wroblewski

Victor Wroblewski has a long and varied work experience. Victor has been Senior Vice President and Head of Biology at SPARX Therapeutics since 2020, and before that, they were VP, Biotherapeutics Development, LBA at AIT Bioscience. From 2018-2020, they were a Research Fellow at the Indiana Biosciences Research Institute as part of the IBRI Pharmaceutical Biotechnology Center, where they led a group of scientists in the discovery and engineering of monoclonal antibodies for optimal PK/PD properties. Prior to this, they were a Distinguished Fellow and Distinguished Research Fellow at Eli Lilly and Company from 1998-2018, where they directed a team of 30 scientists and supported the preclinical development of Lilly's biotechnology portfolio.

Victor Wroblewski obtained their Doctor of Philosophy - PhD in Pharmacology from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo between 1982 and 1987.